TABLE 2

Adverse Events During and After 223Ra Treatment

Adverse eventIncidence (n = 26)
Drug-related
 Treatment-emergent*15 (58%)
 Serious†3 (12%)
Bone-associated events6 (23%)
 Fractures2 (8%)
 Bone disorders‡4 (15%)

  • *During 223Ra therapy and up to 30 d after last 223Ra dose.

  • ↵†During 223Ra therapy and up to 7 y after last 223Ra dose.

  • ↵‡Excluding congenital disorders and fractures, according to Medical Dictionary for Regulatory Activities, version 21.1 (https://www.meddra.org/).

  • Qualitative data are number and percentage.